Trial reportDrug design, development and therapy2025
Determination the ED90s of Different Concentrations of Initial Ropivacaine Volume for Labor Analgesia with Dural Puncture Epidural: A Randomized Sequential Allocation Study.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effective Dose 90 of Programmed Intermittent Epidural Bolus Volume at Three Ropivacaine Concentrations with Dural Puncture Epidural for Labor Analgesia: A Randomized Sequential Allocation Study.Drug design, development and therapy · 2026Trial
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to determine the 90% effective doses (ED Methods: Ninety ASA II-class patients with cervical dilation < 5 cm and VAS scores >5 were allocated into three groups (0.075%, 0.1%, and 0.125% ropivacaine concentrations) for epidural labor analgesia. The first patient in each group received an initial bolus of ropivacaine combined with sufentanil 0.3 µg/mL in a 10 mL volume. Subsequent doses were determined by an up-and-down sequential allocation method based on adequate analgesia (VAS score <3) within 30 minutes post-administration, using 2 mL incremental/decremental adjustments. The primary outcome was the ED90s of the initial ropivacaine bolus required for effective analgesia under DPE. Maternal analgesia characteristics and neonatal outcomes were recorded. Results: The ED90 values for the 0.075%, 0.1%, and 0.125% ropivacaine groups were 13.30 mL (95% CI, 10.00-14.00), 10.80 mL (95% CI, 8.00-12.00), and 8.90 mL (95% CI, 8.00-10.00), respectively. Maternal and neonatal outcomes were comparable across groups. Conclusion: Compared to 0.075% concentration of ropivacaine, the 0.1% and 0.125% concentrations achieved 18.8% and 33.0% reductions in initial analgesic volume requirements. However, comparable analgesic effects and maternal satisfaction were observed across all groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.